Aktuellt
SENASTE
Redeye provides a short comment on Ortoma’s Q3 report this morning. There are several essential steps in the quarter. Firstly, the net sales figure came in below what we expected, but it is still early, and the sales will be lumpy. More important in our view is the continued payments of milestones and the communicated order during the quarter. Another critical point is a strong cash flow that brings the cash at hand to a reasonable level. The quarter and the first nine months’ EBITDA are positive, along with the milestone and other net sales. We expect to change our estimates as the outcome was below our expectations; however, the effect on the Fair value range and the Base case will be minor, if any. The current Base case is SEK 20 per share.
LÄS MER
